GlobeNewswire Inc.··NaPharming Charts Growth Despite RUCONEST Decline, Bets on Joenja Expansion
Pharming Group's Q1 2026 revenues fell 8% YoY to $72.4M, hurt by RUCONEST decline, but Joenja surged 34%. Company maintains full-year guidance and advances international launches.
PHAR2026 guidancecash flow positive